Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer

被引：2
|
作者：
Miaris, Nikolaos [1 ]
Sgouros, Joseph [1 ]
Gerolympou, Margarita [1 ]
Spyropoulos, Basilios [2 ]
Drakopoulos, Dionysios [3 ]
Gkoura, Stefania [1 ]
Res, Helen [1 ]
Samantas, Epaminondas [1 ]
机构：
[1] Agioi Anargyroi Gen Oncol Hosp Kifisia, Dept Med Oncol 3, Noufaron & Timiou Stavrou 14, Athens 14564, Greece
[2] 401 Gen Mil Hosp Athens, Dept Internal Med 1, Athens, Greece
[3] 401 Gen Mil Hosp Athens, Dept Radiol, Athens, Greece
来源：
JOURNAL OF GASTROINTESTINAL CANCER | 2019年 / 50卷 / 01期
关键词：
LEUKOENCEPHALOPATHY SYNDROME; OXALIPLATIN;
D O I：
10.1007/s12029-017-9986-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：123 / 126
页数：4
相关论文
共 50 条
  • [31] OUR EXPERIENCE WITH IRINOTECAN AND BOLUS FLUOROURACIL/LEUCOVORIN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Davidov, Deyan
    JOURNAL OF IMAB, 2009, 15 (01): : 49 - 52
  • [32] Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Shouji, Daigo
    Shinozaki, Eiji
    Matsusaka, Satoshi
    Chin, Keisho
    Oya, Masatoshi
    Yamaguchi, Toshiharu
    Muto, Tetsuichiro
    Hatake, Kiyohiko
    JOURNAL OF GASTROENTEROLOGY, 2008, 43 (11) : 842 - 848
  • [33] A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer
    Chen, Emerson Y.
    Blanke, Charles D.
    Haller, Daniel G.
    Benson, Al B.
    Dragovich, Tomislav
    Lenz, Heinz-Josef
    Robles, Carlos
    Li, Hong
    Mori, Motomi
    Mattek, Nora
    Sanborn, Rachel E.
    Lopez, Charles D.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (12): : 1193 - 1198
  • [34] Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
    Seium, Y
    Stupp, R
    Ruhstaller, T
    Gervaz, P
    Mentha, G
    Philippe, M
    Allal, A
    Trembleau, C
    Bauer, J
    Morant, R
    Roth, AD
    ANNALS OF ONCOLOGY, 2005, 16 (05) : 762 - 766
  • [35] Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
    Nicolas Tsavaris
    Christos Kosmas
    Maria Vadiaka
    Christos Koufos
    BMC Cancer, 2
  • [36] Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan
    Mitsukuni Suenaga
    Nobuyuki Mizunuma
    Daigo Shouji
    Eiji Shinozaki
    Satoshi Matsusaka
    Keisho Chin
    Masatoshi Oya
    Toshiharu Yamaguchi
    Tetsuichiro Muto
    Kiyohiko Hatake
    Journal of Gastroenterology, 2008, 43 : 842 - 848
  • [37] Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
    Tsavaris, N
    Kosmas, C
    Vadiaka, M
    Koufos, C
    BMC CANCER, 2002, 2 (1)
  • [38] Phase II study of irinotecan for metastatic colorectal cancer after unsuccessful treatment with 5-fluorouracil
    Ziras, N
    Paraschos, M
    Tsitoura, M
    Papadouris, S
    Giannakakis, T
    2ND BALKAN CONGRESS OF ONCOLOGY, 1999, : 479 - 482
  • [39] LEUCOVORIN PLUS 5-FLUOROURACIL - AN EFFECTIVE TREATMENT FOR METASTATIC COLON CANCER
    LAUFMAN, LR
    KRZECZOWSKI, KA
    ROACH, R
    SEGAL, M
    JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) : 1394 - 1400
  • [40] Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer
    Douillard, JY
    ONCOLOGY-NEW YORK, 2000, 14 (12): : 51 - 55
12345